TG Therapeutics Conference Call Summary Company Overview - **Company**: TG Therapeutics (NasdaqCM:TGTX) - **Focus**: B-cell mediated diseases, primarily multiple sclerosis (MS) - **Approved Drug**: Briumvi, an anti-CD20 monoclonal antibody for MS, launched in January 2023 - **Market Presence**: Available in 16 countries, with over 20,000 patients prescribed Briumvi to date [2][3] Core Market Insights - **Anti-CD20 Market**: Represents approximately $10 billion in sales, with Briumvi capturing about 20% of the total market share and one-third of the healthcare provider-administered segment [4][6] - **Growth Potential**: The anti-CD20 class holds a 50% market share in new prescriptions, indicating room for growth [4][5] Financial Performance - **2026 Revenue**: Total global revenues of $616 million, with U.S. net revenue of $594 million, reflecting a 90% year-over-year growth [7][9] - **Cumulative Revenue**: Exceeded $1 billion in cumulative net sales within less than three years of launch [6][7] - **Forecast for 2026**: Targeting $875 million to $900 million in global net revenue, primarily from U.S. sales [27][28] Product Development and Future Plans - **Upcoming Trials**: - Enhanced IV protocol aimed at consolidating dosing to simplify onboarding, with top-line data expected mid-2026 [18][19] - Development of a self-administered subcutaneous (subcu) version of Briumvi, with a pivotal study currently over 50% enrolled and a target launch in 2028 [20][21] - **Expansion Beyond MS**: Plans to explore additional indications for Briumvi, including myasthenia gravis (MG) and neuromyelitis optica (NMO) [25][26] Competitive Landscape - **Market Positioning**: Briumvi is positioned as the lowest-priced branded MS treatment, enhancing its appeal in a competitive market [12][13] - **Sales Force Strategy**: Plans to increase the sales force by 10%-20% to target high-opportunity healthcare providers [14][34] R&D and Pipeline - **Azer-cel**: An allogeneic off-the-shelf CD19 CAR-T product in development for progressive MS, with data expected in 2026 [25][44] - **Long-term Opportunities**: Patents extending into the mid-2040s, with ongoing evaluations for new indications and potential drug launches [31] Key Takeaways - **Market Dynamics**: Briumvi's growth trajectory is strong, with significant market share gains and a robust pipeline for future growth [30][31] - **Operational Efficiency**: The company maintains low operating expenses relative to revenue, indicating potential for profitability acceleration [31][29] - **Patient Engagement**: Emphasis on patient awareness campaigns to drive market share, recognizing the importance of shared decision-making in MS treatment [15][16] Conclusion - TG Therapeutics is well-positioned for continued growth in the MS market with Briumvi, supported by strategic product development and a focus on patient and healthcare provider engagement. The company anticipates significant revenue growth and operational efficiency in the coming years, with a strong pipeline of future products and indications.

Core Viewpoint - WuXi AppTec's subsidiary, WuXi Biologics, has seen its stock price rise significantly following the announcement of its CAR-T product, Beinuoda, being included in the first version of the National Healthcare Security Administration's commercial health insurance innovative drug list [1] Group 1: Company Developments - WuXi Biologics' stock price increased by over 9% in early trading, currently up 7.79% at HKD 3.32, with a trading volume of HKD 2.6756 million [1] - The company announced that its first domestically developed CAR-T product, Beinuoda (Rikioranase injection), has been successfully included in the innovative drug list by the National Healthcare Security Administration [1] Group 2: Product Information - Beinuoda is currently the only CAR-T product in China approved for three non-Hodgkin lymphoma indications, including relapsed/refractory large B-cell lymphoma, relapsed/refractory follicular lymphoma, and relapsed/refractory mantle cell lymphoma [1] - Prior to its inclusion in the national commercial insurance innovative drug list, Beinuoda had already been recognized for its significant clinical value, being included in over 100 universal insurance plans and nearly 100 million medical insurance plans, demonstrating extensive clinical practice and real-world research validation among Chinese patients [1]

（文章来源：北京商报） 具体来看，包括复星凯瑞的阿基仑赛注射液、药明巨诺的瑞基奥仑赛注射液、驯鹿生物的伊基奥仑赛注 射液、合源生物的纳基奥仑赛注射液、以及恺兴生命科技的泽沃基奥仑赛注射液。 北京商报讯12月7日，《商业健康保险创新药品目录（2025年）》正式发布，18家创新药企业的19款药 品成功纳入，其中包括五款CAR-T产品。 ...